Yumab – new international member

5 January 2024
New member

YUMAB develops therapeutic antibodies for its clients and partners using one of the world’s largest human antibody libraries (>10e11), patient-derived libraries or immune libraries.
YUMAB bridges the gap between research innovation and novel therapies. Our advanced discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.
From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner. To know more